The  ||| S:0 E:4 ||| DT
importance  ||| S:4 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
detecting  ||| S:18 E:28 ||| VBG
cytomegalovirus  ||| S:28 E:44 ||| JJ
infections  ||| S:44 E:55 ||| NNS
in  ||| S:55 E:58 ||| IN
studies  ||| S:58 E:66 ||| NNS
evaluating  ||| S:66 E:77 ||| VBG
new  ||| S:77 E:81 ||| JJ
therapies  ||| S:81 E:91 ||| NNS
for  ||| S:91 E:95 ||| IN
severe  ||| S:95 E:102 ||| JJ
sepsis  ||| S:102 E:109 ||| JJ
Cytomegalovirus  ||| S:109 E:125 ||| JJ
infection  ||| S:125 E:135 ||| NN
is  ||| S:135 E:138 ||| VBZ
present  ||| S:138 E:146 ||| JJ
in  ||| S:146 E:149 ||| IN
the  ||| S:149 E:153 ||| DT
majority  ||| S:153 E:162 ||| NN
of  ||| S:162 E:165 ||| IN
the  ||| S:165 E:169 ||| DT
population  ||| S:169 E:180 ||| NN
and  ||| S:180 E:184 ||| CC
is  ||| S:184 E:187 ||| VBZ
associated  ||| S:187 E:198 ||| VBN
with  ||| S:198 E:203 ||| IN
substantial  ||| S:203 E:215 ||| JJ
morbidity  ||| S:215 E:225 ||| NN
and  ||| S:225 E:229 ||| CC
mortality  ||| S:229 E:239 ||| NN
in  ||| S:239 E:242 ||| IN
immunocompromised  ||| S:242 E:260 ||| JJ
patients ||| S:260 E:268 ||| NNS
.  ||| S:268 E:270 ||| .
Recently ||| S:270 E:278 ||| RB
,  ||| S:278 E:280 ||| ,
this  ||| S:280 E:285 ||| DT
viral  ||| S:285 E:291 ||| JJ
infection  ||| S:291 E:301 ||| NN
has  ||| S:301 E:305 ||| VBZ
also  ||| S:305 E:310 ||| RB
been  ||| S:310 E:315 ||| VBN
reported  ||| S:315 E:324 ||| VBN
in  ||| S:324 E:327 ||| IN
nonimmunocompromised  ||| S:327 E:348 ||| VBG
critically  ||| S:348 E:359 ||| RB
ill  ||| S:359 E:363 ||| JJ
patients ||| S:363 E:371 ||| NNS
.  ||| S:371 E:373 ||| .
We  ||| S:373 E:376 ||| PRP
hypothesize  ||| S:376 E:388 ||| VBD
that  ||| S:388 E:393 ||| DT
active  ||| S:393 E:400 ||| JJ
cytomegalovirus  ||| S:400 E:416 ||| JJ
infection  ||| S:416 E:426 ||| NN
may  ||| S:426 E:430 ||| MD
confound  ||| S:430 E:439 ||| VB
survival  ||| S:439 E:448 ||| NN
outcomes  ||| S:448 E:457 ||| NNS
in  ||| S:457 E:460 ||| IN
severe  ||| S:460 E:467 ||| JJ
sepsis  ||| S:467 E:474 ||| NN
trials ||| S:474 E:480 ||| NNS
.  ||| S:480 E:482 ||| .
Scenarios  ||| S:482 E:492 ||| NNS
based  ||| S:492 E:498 ||| VBN
on  ||| S:498 E:501 ||| IN
three  ||| S:501 E:507 ||| CD
published  ||| S:507 E:517 ||| VBN
studies  ||| S:517 E:525 ||| NNS
on  ||| S:525 E:528 ||| IN
activated  ||| S:528 E:538 ||| JJ
protein  ||| S:538 E:546 ||| NN
C  ||| S:546 E:548 ||| NNP
were  ||| S:548 E:553 ||| VBD
used  ||| S:553 E:558 ||| VBN
as  ||| S:558 E:561 ||| IN
real  ||| S:561 E:566 ||| JJ
examples  ||| S:566 E:575 ||| NNS
for  ||| S:575 E:579 ||| IN
statistical  ||| S:579 E:591 ||| JJ
simulations  ||| S:591 E:603 ||| NNS
looking  ||| S:603 E:611 ||| VBG
for  ||| S:611 E:615 ||| IN
how  ||| S:615 E:619 ||| WRB
much  ||| S:619 E:624 ||| JJ
bias  ||| S:624 E:629 ||| NN
in  ||| S:629 E:632 ||| IN
favor  ||| S:632 E:638 ||| NN
of  ||| S:638 E:641 ||| IN
or  ||| S:641 E:644 ||| CC
against  ||| S:644 E:652 ||| IN
activated  ||| S:652 E:662 ||| JJ
protein  ||| S:662 E:670 ||| NN
C  ||| S:670 E:672 ||| NNP
would  ||| S:672 E:678 ||| MD
be  ||| S:678 E:681 ||| VB
observed  ||| S:681 E:690 ||| VBN
in  ||| S:690 E:693 ||| IN
single-arm  ||| S:693 E:704 ||| JJ
studies  ||| S:704 E:712 ||| NNS
( ||| S:712 E:713 ||| -LRB-
scenario  ||| S:713 E:722 ||| NN
1 ||| S:722 E:723 ||| CD
) ||| S:723 E:724 ||| -RRB-
,  ||| S:724 E:726 ||| ,
phase  ||| S:726 E:732 ||| NN
II  ||| S:732 E:735 ||| NNP
trials  ||| S:735 E:742 ||| NNS
( ||| S:742 E:743 ||| -LRB-
scenario  ||| S:743 E:752 ||| FW
2A ||| S:752 E:754 ||| FW
/ ||| S:754 E:755 ||| FW
2B ||| S:755 E:757 ||| FW
) ||| S:757 E:758 ||| -RRB-
,  ||| S:758 E:760 ||| ,
and  ||| S:760 E:764 ||| CC
phase  ||| S:764 E:770 ||| NN
III  ||| S:770 E:774 ||| NNP
trials  ||| S:774 E:781 ||| NNS
( ||| S:781 E:782 ||| -LRB-
scenario  ||| S:782 E:791 ||| FW
3A ||| S:791 E:793 ||| FW
/ ||| S:793 E:794 ||| FW
3B ||| S:794 E:796 ||| FW
) ||| S:796 E:797 ||| -RRB-
.  ||| S:797 E:799 ||| .
Scenario  ||| S:799 E:808 ||| NNP
1  ||| S:808 E:810 ||| CD
simulations  ||| S:810 E:822 ||| NNS
evaluated  ||| S:822 E:832 ||| VBD
a  ||| S:832 E:834 ||| DT
single-arm  ||| S:834 E:845 ||| JJ
study  ||| S:845 E:851 ||| NN
and  ||| S:851 E:855 ||| CC
demonstrated  ||| S:855 E:868 ||| VBN
that  ||| S:868 E:873 ||| IN
confounding  ||| S:873 E:885 ||| JJ
biases  ||| S:885 E:892 ||| NNS
could  ||| S:892 E:898 ||| MD
cause  ||| S:898 E:904 ||| VB
an  ||| S:904 E:907 ||| DT
absolute  ||| S:907 E:916 ||| JJ
decrease  ||| S:916 E:925 ||| NN
of  ||| S:925 E:928 ||| IN
5.7 ||| S:928 E:931 ||| CD
%  ||| S:931 E:933 ||| NN
to  ||| S:933 E:936 ||| TO
an  ||| S:936 E:939 ||| DT
increase  ||| S:939 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
6.1 ||| S:951 E:954 ||| CD
%  ||| S:954 E:956 ||| NN
on  ||| S:956 E:959 ||| IN
mortality  ||| S:959 E:969 ||| NN
rates  ||| S:969 E:975 ||| NNS
of  ||| S:975 E:978 ||| IN
similar  ||| S:978 E:986 ||| JJ
studies ||| S:986 E:993 ||| NNS
.  ||| S:993 E:995 ||| .
Scenarios  ||| S:995 E:1005 ||| NNP
2A  ||| S:1005 E:1008 ||| NNP
and  ||| S:1008 E:1012 ||| CC
3A  ||| S:1012 E:1015 ||| CD
evaluated  ||| S:1015 E:1025 ||| JJ
phase  ||| S:1025 E:1031 ||| NN
II  ||| S:1031 E:1034 ||| NNP
and  ||| S:1034 E:1038 ||| CC
III  ||| S:1038 E:1042 ||| NNP
trials  ||| S:1042 E:1049 ||| NNS
assuming  ||| S:1049 E:1058 ||| VBG
that  ||| S:1058 E:1063 ||| IN
activated  ||| S:1063 E:1073 ||| JJ
protein  ||| S:1073 E:1081 ||| NN
C  ||| S:1081 E:1083 ||| NNP
is  ||| S:1083 E:1086 ||| VBZ
truly  ||| S:1086 E:1092 ||| RB
effective ||| S:1092 E:1101 ||| JJ
;  ||| S:1101 E:1103 ||| :
they  ||| S:1103 E:1108 ||| PRP
showed  ||| S:1108 E:1115 ||| VBD
that  ||| S:1115 E:1120 ||| IN
trials  ||| S:1120 E:1127 ||| NNS
with  ||| S:1127 E:1132 ||| IN
an  ||| S:1132 E:1135 ||| DT
imbalance  ||| S:1135 E:1145 ||| NN
on  ||| S:1145 E:1148 ||| IN
the  ||| S:1148 E:1152 ||| DT
proportion  ||| S:1152 E:1163 ||| NN
of  ||| S:1163 E:1166 ||| IN
active  ||| S:1166 E:1173 ||| JJ
cytomegalovirus  ||| S:1173 E:1189 ||| JJ
infection  ||| S:1189 E:1199 ||| NN
between  ||| S:1199 E:1207 ||| IN
study  ||| S:1207 E:1213 ||| NN
arms  ||| S:1213 E:1218 ||| NNS
could  ||| S:1218 E:1224 ||| MD
lead  ||| S:1224 E:1229 ||| VB
to  ||| S:1229 E:1232 ||| TO
false-negative  ||| S:1232 E:1247 ||| JJ
rates  ||| S:1247 E:1253 ||| NNS
( ||| S:1253 E:1254 ||| -LRB-
β  ||| S:1254 E:1256 ||| JJ
errors ||| S:1256 E:1262 ||| NNS
)  ||| S:1262 E:1264 ||| -RRB-
in  ||| S:1264 E:1267 ||| IN
up  ||| S:1267 E:1270 ||| RB
to  ||| S:1270 E:1273 ||| TO
25 ||| S:1273 E:1275 ||| CD
%  ||| S:1275 E:1277 ||| NN
of  ||| S:1277 E:1280 ||| IN
phase  ||| S:1280 E:1286 ||| NN
II  ||| S:1286 E:1289 ||| NNP
trials  ||| S:1289 E:1296 ||| NNS
and  ||| S:1296 E:1300 ||| CC
up  ||| S:1300 E:1303 ||| RB
to  ||| S:1303 E:1306 ||| TO
42 ||| S:1306 E:1308 ||| CD
%  ||| S:1308 E:1310 ||| NN
of  ||| S:1310 E:1313 ||| IN
phase  ||| S:1313 E:1319 ||| NN
III  ||| S:1319 E:1323 ||| NNP
trials ||| S:1323 E:1329 ||| NNS
.  ||| S:1329 E:1331 ||| .
Scenarios  ||| S:1331 E:1341 ||| NNP
2B  ||| S:1341 E:1344 ||| NNP
and  ||| S:1344 E:1348 ||| CC
3B  ||| S:1348 E:1351 ||| NNP
assumed  ||| S:1351 E:1359 ||| VBD
that  ||| S:1359 E:1364 ||| DT
activated  ||| S:1364 E:1374 ||| JJ
protein  ||| S:1374 E:1382 ||| NN
C  ||| S:1382 E:1384 ||| NNP
was  ||| S:1384 E:1388 ||| VBD
truly  ||| S:1388 E:1394 ||| RB
ineffective ||| S:1394 E:1405 ||| JJ
;  ||| S:1405 E:1407 ||| :
they  ||| S:1407 E:1412 ||| PRP
showed  ||| S:1412 E:1419 ||| VBD
that  ||| S:1419 E:1424 ||| DT
imbalanced  ||| S:1424 E:1435 ||| JJ
cytomegalovirus  ||| S:1435 E:1451 ||| JJ
infection  ||| S:1451 E:1461 ||| NN
between  ||| S:1461 E:1469 ||| IN
arms  ||| S:1469 E:1474 ||| NNS
would  ||| S:1474 E:1480 ||| MD
cause  ||| S:1480 E:1486 ||| VB
false-positive  ||| S:1486 E:1501 ||| JJ
rates  ||| S:1501 E:1507 ||| NNS
( ||| S:1507 E:1508 ||| -LRB-
α  ||| S:1508 E:1510 ||| JJ
errors ||| S:1510 E:1516 ||| NNS
)  ||| S:1516 E:1518 ||| -RRB-
in  ||| S:1518 E:1521 ||| IN
up  ||| S:1521 E:1524 ||| RB
to  ||| S:1524 E:1527 ||| TO
5 ||| S:1527 E:1528 ||| CD
%  ||| S:1528 E:1530 ||| NN
of  ||| S:1530 E:1533 ||| IN
phase  ||| S:1533 E:1539 ||| NN
II  ||| S:1539 E:1542 ||| NNP
and  ||| S:1542 E:1546 ||| CC
up  ||| S:1546 E:1549 ||| RB
to  ||| S:1549 E:1552 ||| TO
7 ||| S:1552 E:1553 ||| CD
%  ||| S:1553 E:1555 ||| NN
of  ||| S:1555 E:1558 ||| IN
all  ||| S:1558 E:1562 ||| DT
phase  ||| S:1562 E:1568 ||| NN
III  ||| S:1568 E:1572 ||| NNP
trials ||| S:1572 E:1578 ||| NNS
.  ||| S:1578 E:1580 ||| .
The  ||| S:1580 E:1584 ||| DT
inclusion  ||| S:1584 E:1594 ||| NN
of  ||| S:1594 E:1597 ||| IN
an  ||| S:1597 E:1600 ||| DT
imbalanced  ||| S:1600 E:1611 ||| JJ
proportion  ||| S:1611 E:1622 ||| NN
of  ||| S:1622 E:1625 ||| IN
patients  ||| S:1625 E:1634 ||| NNS
with  ||| S:1634 E:1639 ||| IN
active  ||| S:1639 E:1646 ||| JJ
cytomegalovirus  ||| S:1646 E:1662 ||| JJ
infection  ||| S:1662 E:1672 ||| NN
may  ||| S:1672 E:1676 ||| MD
severely  ||| S:1676 E:1685 ||| RB
compromise  ||| S:1685 E:1696 ||| VB
the  ||| S:1696 E:1700 ||| DT
reliability  ||| S:1700 E:1712 ||| NN
of  ||| S:1712 E:1715 ||| IN
outcome  ||| S:1715 E:1723 ||| NN
results  ||| S:1723 E:1731 ||| NNS
of  ||| S:1731 E:1734 ||| IN
severe  ||| S:1734 E:1741 ||| JJ
sepsis  ||| S:1741 E:1748 ||| NN
trials  ||| S:1748 E:1755 ||| NNS
independent  ||| S:1755 E:1767 ||| JJ
of  ||| S:1767 E:1770 ||| IN
their  ||| S:1770 E:1776 ||| PRP$
design ||| S:1776 E:1782 ||| NN
.  ||| S:1782 E:1784 ||| .
Even  ||| S:1784 E:1789 ||| RB
randomized  ||| S:1789 E:1800 ||| JJ
trials  ||| S:1800 E:1807 ||| NNS
could  ||| S:1807 E:1813 ||| MD
have  ||| S:1813 E:1818 ||| VB
a  ||| S:1818 E:1820 ||| DT
much  ||| S:1820 E:1825 ||| RB
higher  ||| S:1825 E:1832 ||| JJR
probability  ||| S:1832 E:1844 ||| NN
of  ||| S:1844 E:1847 ||| IN
false-negative  ||| S:1847 E:1862 ||| JJ
rates  ||| S:1862 E:1868 ||| NNS
for  ||| S:1868 E:1872 ||| IN
a  ||| S:1872 E:1874 ||| DT
new  ||| S:1874 E:1878 ||| JJ
therapy  ||| S:1878 E:1886 ||| NN
than  ||| S:1886 E:1891 ||| IN
designed ||| S:1891 E:1899 ||| VBN
.  ||| S:1899 E:1901 ||| .
Future  ||| S:1901 E:1908 ||| JJ
severe  ||| S:1908 E:1915 ||| JJ
sepsis  ||| S:1915 E:1922 ||| NN
trials  ||| S:1922 E:1929 ||| NNS
should  ||| S:1929 E:1936 ||| MD
consider  ||| S:1936 E:1945 ||| VB
including  ||| S:1945 E:1955 ||| VBG
active  ||| S:1955 E:1962 ||| JJ
cytomegalovirus  ||| S:1962 E:1978 ||| JJ
infection  ||| S:1978 E:1988 ||| NN
as  ||| S:1988 E:1991 ||| IN
a  ||| S:1991 E:1993 ||| DT
prospective  ||| S:1993 E:2005 ||| JJ
covariate ||| S:2005 E:2014 ||| NN
.  ||| S:2014 E:2016 ||| .
